BioAtla, Inc. Overview
Pro stress-test →BioAtla is a clinical-stage biopharmaceutical company that develops specific and selective antibody-based therapeutics for treating solid tumor cancer. The company leverages proprietary Conditionally Active Biologics (CAB) and antibody-drug conjugate (ADC) technologies to address difficult-to-treat malignancies with improved targeting specificity.
Strategic Profile
Pro stress-test →The company's lead clinical-stage product candidates include mecbotamab vedotin (BA3011), a CAB ADC for treating undifferentiated pleomorphic sarcoma and NSCLC, and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. BioAtla achieved FDA alignment on a planned randomized Phase 3 Oz-V trial in 2L+ OPSCC with dual primary endpoints and potential accelerated approval.
Competitive Landscape
Pro stress-test →BioAtla operates in the solid tumor oncology space alongside other ADC and immunotherapy developers. The company faces competition from established players developing ADCs (Seagen, Pfizer) and emerging CAB-focused players, though its conditionally-active approach provides differentiation through reduced off-target toxicity.
Industry Context
BioAtla, Inc. operates in Biopharmaceutical - Oncology/Immuno-Oncology.
Key facts
Founded: 2007 · Headquarters: San Diego, California · Market cap: $12.65M